Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793402 | 0.94 | IGF1R (0.36) | PTGDR2IGF1REEDSCN9ATP53 | |
| SCHEMBL1748804 | 0.84 | IGF1R (0.39) | PTGDR2IGF1REEDSCN9ATP53 | |
| SCHEMBL1750570 | 0.82 | IGF1R (0.34) | PTGDR2IGF1REEDSCN9ATP53 | |
| SCHEMBL1748807 | 0.82 | PTGDR2 (0.31) | PTGDR2IGF1RTP53 | |
| SCHEMBL1749798 | 0.81 | PTGDR2 (0.39) | PTGDR2IGF1RSCN9ATP53 | |
| SCHEMBL1749211 | 0.80 | IGF1R (0.39) | PTGDR2IGF1REEDSCN9ATP53 | |
| SCHEMBL1749257 | 0.80 | IGF1R (0.39) | PTGDR2IGF1REEDTP53ALDH1A1 | |
| SCHEMBL1748824 | 0.80 | IGF1R (0.39) | PTGDR2IGF1REEDTP53SMN1; SMN2 | |
| SCHEMBL1748968 | 0.79 | IGF1R (0.37) | PTGDR2IGF1REEDTP53ALDH1A1 | |
| SCHEMBL1748813 | 0.79 | IGF1R (0.37) | PTGDR2IGF1REEDSCN9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968566-B2 | Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7528147-B2 | Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-05-05 | — | — | US | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K1 | PTGDR2 806/4885IGF1R 817/4885EED 4472/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | PTGDR2 806/4885IGF1R 817/4885EED 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.